A detailed history of Baker Tilly Wealth Management, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Baker Tilly Wealth Management, LLC holds 2,851 shares of BIIB stock, worth $652,365. This represents 0.11% of its overall portfolio holdings.

Number of Shares
2,851
Previous 2,881 1.04%
Holding current value
$652,365
Previous $745,000 17.58%
% of portfolio
0.11%
Previous 0.12%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$212.02 - $267.71 $6,360 - $8,031
-30 Reduced 1.04%
2,851 $614,000
Q4 2023

Jan 10, 2024

SELL
$222.59 - $267.94 $53,644 - $64,573
-241 Reduced 7.72%
2,881 $745,000
Q3 2023

Oct 10, 2023

BUY
$253.3 - $285.89 $4,052 - $4,574
16 Added 0.52%
3,122 $802,000
Q2 2023

Jul 20, 2023

BUY
$275.25 - $318.06 $7,707 - $8,905
28 Added 0.91%
3,106 $884,000
Q1 2023

Apr 12, 2023

SELL
$256.56 - $292.34 $4,618 - $5,262
-18 Reduced 0.58%
3,078 $855,000
Q4 2022

Jan 26, 2023

BUY
$252.44 - $306.72 $4,543 - $5,520
18 Added 0.58%
3,096 $0
Q3 2022

Oct 20, 2022

SELL
$194.69 - $268.46 $17,716 - $24,429
-91 Reduced 2.87%
3,078 $822,000
Q2 2022

Jul 28, 2022

SELL
$187.54 - $223.02 $4,688 - $5,575
-25 Reduced 0.78%
3,169 $646,000
Q1 2022

Apr 27, 2022

BUY
$193.77 - $244.14 $291,623 - $367,430
1,505 Added 89.11%
3,194 $673,000
Q4 2021

Feb 08, 2022

SELL
$223.92 - $287.77 $211,380 - $271,654
-944 Reduced 35.85%
1,689 $405,000
Q3 2021

Nov 02, 2021

BUY
$282.99 - $369.05 $114,044 - $148,727
403 Added 18.07%
2,633 $745,000
Q2 2021

Jul 30, 2021

BUY
$259.0 - $414.71 $67,081 - $107,409
259 Added 13.14%
2,230 $772,000
Q1 2021

Apr 28, 2021

BUY
$242.95 - $284.63 $46,889 - $54,933
193 Added 10.85%
1,971 $551,000
Q4 2020

Feb 03, 2021

BUY
$236.26 - $355.63 $420,070 - $632,310
1,778 New
1,778 $435,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $33B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Baker Tilly Wealth Management, LLC Portfolio

Follow Baker Tilly Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Tilly Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baker Tilly Wealth Management, LLC with notifications on news.